Production (Stage)
Xeris Biopharma Holdings, Inc.
XERS
$4.83
-$0.05-1.03%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 0.03% | 10.74% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 0.03% | 10.74% | |||
| Cost of Revenue | -7.91% | -30.27% | |||
| Gross Profit | 1.52% | 24.45% | |||
| SG&A Expenses | 29.32% | -24.31% | |||
| Depreciation & Amortization | -0.04% | 0.00% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 20.81% | -22.10% | |||
| Operating Income | -139.72% | 160.34% | |||
| Income Before Tax | -80.32% | 73.18% | |||
| Income Tax Expenses | -- | 100.00% | |||
| Earnings from Continuing Operations | -80.32% | 67.51% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -80.32% | 67.51% | |||
| EBIT | -139.72% | 160.34% | |||
| EBITDA | -100.60% | 209.40% | |||
| EPS Basic | -76.38% | 67.52% | |||
| Normalized Basic EPS | -1,021.95% | 105.02% | |||
| EPS Diluted | -76.38% | 67.52% | |||
| Normalized Diluted EPS | -1,021.95% | 105.02% | |||
| Average Basic Shares Outstanding | 2.25% | 0.07% | |||
| Average Diluted Shares Outstanding | 2.25% | 0.07% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||